OppenheimerFunds Inc. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,038,387 shares of the biopharmaceutical company’s stock after acquiring an additional 22,916 shares during the quarter. OppenheimerFunds Inc. owned approximately 0.54% of Gilead Sciences worth $498,599,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also made changes to their positions in GILD. Archford Capital Strategies LLC bought a new position in Gilead Sciences in the first quarter worth $106,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in Gilead Sciences in the second quarter worth $132,000. Brand Asset Management Group Inc. bought a new position in Gilead Sciences in the second quarter worth $139,000. Stelac Advisory Services LLC purchased a new stake in shares of Gilead Sciences in the first quarter worth $141,000. Finally, Mckinley Capital Management LLC Delaware grew its stake in shares of Gilead Sciences by 67.7% in the first quarter. Mckinley Capital Management LLC Delaware now owns 2,130 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 860 shares during the last quarter. Institutional investors own 78.04% of the company’s stock.
Gilead Sciences stock opened at $74.29 on Wednesday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.92 and a current ratio of 3.00. Gilead Sciences, Inc. has a one year low of $64.27 and a one year high of $89.54. The firm has a market cap of $98.17 billion, a P/E ratio of 8.68, a price-to-earnings-growth ratio of -5.77 and a beta of 1.02.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, July 25th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the consensus estimate of $1.56 by $0.35. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%. The company had revenue of $5.65 billion for the quarter, compared to analysts’ expectations of $5.20 billion. During the same period last year, the firm posted $2.56 earnings per share. Gilead Sciences’s revenue was down 20.9% compared to the same quarter last year. equities analysts anticipate that Gilead Sciences, Inc. will post 6.56 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 27th. Investors of record on Friday, September 14th will be given a dividend of $0.57 per share. The ex-dividend date is Thursday, September 13th. This represents a $2.28 annualized dividend and a dividend yield of 3.07%. Gilead Sciences’s dividend payout ratio (DPR) is presently 26.64%.
In related news, Director John C. Martin sold 50,000 shares of the stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $77.85, for a total transaction of $3,892,500.00. Following the sale, the director now directly owns 3,067,762 shares of the company’s stock, valued at $238,825,271.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.16% of the company’s stock.
A number of research firms have recently commented on GILD. BidaskClub raised Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, July 10th. ValuEngine cut Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Monday, August 20th. Mizuho set a $94.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research note on Tuesday, July 31st. Robert W. Baird cut Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 target price on the stock. in a research note on Thursday, July 26th. Finally, Wells Fargo & Co increased their target price on Gilead Sciences from $89.00 to $95.00 and gave the stock an “outperform” rating in a research note on Thursday, July 26th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company’s stock. Gilead Sciences presently has a consensus rating of “Buy” and a consensus price target of $88.30.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Article: How to Invest in an Index Fund
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.